Spots Global Cancer Trial Database for egfr
Every month we try and update this database with for egfr cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | NCT05316480 | Pancreatic Neur... | Nimotuzumab | 18 Years - 80 Years | Fudan University | |
| T790M Mutation Positive 2nd Line STandard of cAre Registry | NCT02368990 | Non Small Cell ... | 18 Years - | AstraZeneca | ||
| BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | NCT01562028 | Lung Cancer | Erlotinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | NCT04933422 | Glioblastoma | CM93 | 18 Years - | Crimson Biopharm Inc. | |
| Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations | NCT00891579 | Non Small Cell ... | Pemetrexed (Ali... Gefitinib (IRES... | 18 Years - 80 Years | Chinese Society of Lung Cancer | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. | NCT03381066 | Completely Rese... | gefitinib, peme... Vinorelbine, ci... | 20 Years - | Yonsei University | |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | NCT03974022 | Non-Small Cell ... | Sunvozertinib | 18 Years - | Dizal Pharmaceuticals | |
| Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma | NCT00903292 | Non-Small Cell ... | erlotinib (Tarc... pemetrexed (Ali... | 20 Years - 80 Years | National Cheng-Kung University Hospital | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer | NCT04838548 | Carcinoma, Non-... | MRG003 | 18 Years - | Shanghai Miracogen Inc. | |
| CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR | NCT02331693 | Advanced Glioma | anti-EGFR CAR T | 18 Years - 70 Years | RenJi Hospital | |
| AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer | NCT03986541 | Colorectal Canc... | Immunohistochem... | 18 Years - | University of Leeds | |
| Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | NCT04233021 | Non Small Cell ... Leptomeningeal ... Brain Metastase... EGFR Activating... | Osimertinib | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer | NCT02034097 | Cancer | Foretinib Erlotinib | 18 Years - | GlaxoSmithKline | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC | NCT03046992 | EGFR Gene Mutat... | YH25448 | 20 Years - | Yuhan Corporation | |
| Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer | NCT00215644 | Esophageal Canc... Gastric Cancer | Matuzumab Epirubicin Cisplatin Capecitabine | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors | NCT00728793 | Tumors | CUDC-101 | 18 Years - | Curis, Inc. | |
| An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | NCT02192697 | Non-small Cell ... | ASP8273 | 20 Years - | Astellas Pharma Inc | |
| ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin | NCT00054691 | Skin Cancer | Iressa | 18 Years - | M.D. Anderson Cancer Center | |
| ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | NCT01774721 | Non-small Cell ... | Dacomitinib (PF... Gefitinib | 18 Years - 99 Years | Pfizer | |
| Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer | NCT00739063 | Breast Cancer | Tarceva | - | M.D. Anderson Cancer Center | |
| Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS) | NCT02810262 | Bone Metastases Lung Cancer | Bone metastases... | 18 Years - | Hospices Civils de Lyon | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease | NCT05257967 | EGFR Activating... Leptomeningeal ... Non Small Cell ... | Lumbar puncture... | 18 Years - | British Columbia Cancer Agency | |
| A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive | NCT03812809 | NSCLC | BPI-7711 | 18 Years - | Beta Pharma, Inc. | |
| Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors | NCT00091806 | Tumors Oncology Solid Tumors | panitumumab (AB... Panitumumab | 18 Years - | Amgen | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | NCT02511847 | Triple Negative... | Afatinib | 20 Years - | National Taiwan University Hospital | |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | NCT03319459 | HER2 Positive G... Colorectal Canc... Head and Neck S... EGFR Positive S... Advanced Solid ... HER2-positive B... Hepatocellular ... Non Small Cell ... Renal Cell Carc... Pancreatic Canc... Melanoma | FATE-NK100 Cetuximab Trastuzumab | 18 Years - | Fate Therapeutics | |
| Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab | NCT00491140 | Colorectal Neop... | Gene mutations ... | 18 Years - | Istituto Clinico Humanitas | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. | NCT06281964 | Non-Small-Cell ... | PLB1004 Pemetrexed+（car... | 18 Years - | Avistone Biotechnology Co., Ltd. | |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy | NCT00364013 | Metastatic Colo... | Panitumumab FOLFOX regimen | 18 Years - | Amgen | |
| Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | NCT00444678 | Colorectal Canc... Neoplasm Metast... | Cetuximab Oxaliplatin Capecitabine | 18 Years - | NYU Langone Health | |
| Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA | NCT01238237 | Glioblastoma Mu... ANAPLASTIC ASTR... GBM Anaplastic Astr... | Superselective ... | 18 Years - | Northwell Health | |
| Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity | NCT02183883 | Non-small Cell ... | Afatinib | 18 Years - | University College, London | |
| Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery | NCT04459065 | Lung Cancer | IRDye800CW-nimo... | 18 Years - 80 Years | University of Saskatchewan | |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | NCT04429542 | Head and Neck S... Squamous Cell C... Colorectal Canc... Squamous Cell C... EGFR Amplificat... Epithelial Ovar... Pancreas Cancer Cutaneous Squam... Head and Neck N... Carcinoma, Squa... Squamous Cell C... | BCA101 Pembrolizumab | 18 Years - | Bicara Therapeutics | |
| GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial | NCT02319577 | Non Small Cell ... | oral vinorelbin... Gefitinib | 18 Years - | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | |
| Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II | NCT06195189 | Non Small Cell ... | Sunvozertinib Chemotherapy | 18 Years - 80 Years | Sichuan University | |
| Collection of Blood, Bone Marrow, Tumor or Tissue Samples | NCT00043615 | Neoplasms Precancerous Co... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Anti-EGFR Immunoliposomes in Solid Tumors | NCT01702129 | Solid Tumors | anti-EGFR immun... | 18 Years - | University Hospital, Basel, Switzerland | |
| Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation | NCT05263947 | Carcinoma, Non-... Bevacizumab EGF-R Positive ... Tyrosine Kinase... | Bevacizumab and... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) | NCT03053297 | Carcinoma, Non-... | Patient Reporte... | 18 Years - | AstraZeneca | |
| A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | NCT04036682 | Non Small Cell ... EGFR Exon 20 Mu... | CLN-081 | 18 Years - | Cullinan Therapeutics Inc. | |
| Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | NCT03318939 | NSCLC | Poziotinib | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | NCT05261399 | Carcinoma Non-Small-Cell ... | Savolitinib Osimertinib Pemetrexed Cisplatin Carboplatin | 18 Years - 130 Years | AstraZeneca | |
| OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00036647 | Carcinoma, Non-... | Tarceva (erloti... | 18 Years - | Astellas Pharma Inc | |
| Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients | NCT01702285 | Cancer | CUDC-101 | 18 Years - | Curis, Inc. | |
| HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | NCT04676477 | Non-Small Cell ... | HER3-DXd HER3-DXd Osimertinib Osimertinib HER3-DXd HER3-DXd Osimertinib | 18 Years - | Daiichi Sankyo | |
| A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions | NCT04363242 | Epithelial Carc... Solid Tumor | SYN125 SYN004 | 18 Years - | Synermore Biologics Co., Ltd. | |
| Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC | NCT03046992 | EGFR Gene Mutat... | YH25448 | 20 Years - | Yuhan Corporation | |
| A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | NCT05163028 | Non Small Cell ... Colorectal Canc... Pancreatic Canc... Solid Tumor Cancer Cancer of Pancr... Cancer of Colon | HBI-2376 | 18 Years - | HUYABIO International, LLC. | |
| A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants | NCT06378658 | Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte... | BAY2927088 Esomeprazole Food | 18 Years - 55 Years | Bayer | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms | NCT05987956 | Non-small Cell ... | Alectinib - Usu... Alectinib - Stu... | 22 Years - 75 Years | Medicine Invention Design, Inc | |
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | NCT05079022 | Adenocarcinoma ... | Furmonertinib | 18 Years - | Peking University People's Hospital | |
| Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP) | NCT01103089 | Non-Small Cell ... | - | AstraZeneca | ||
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
| Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients | NCT02022995 | Colon Cancer Ad... | 20 Years - 80 Years | National Taiwan University Hospital | ||
| Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR | NCT00446225 | Non-Small Cell ... | Erlotinib Carboplatin Gemcitabin Docetaxel Cisplatin | 18 Years - | Spanish Lung Cancer Group | |
| First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer | NCT03804580 | Lung Cancer | osimertinib | 18 Years - | Vestre Viken Hospital Trust | |
| Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer | NCT04592666 | Lung Cancer, No... EGFR T790M EGFR Gene Mutat... | Almonertinib Pemetrexed Carboplatin | 18 Years - 75 Years | Fudan University | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | NCT00418938 | Cancer Colon Cancer Colorectal Canc... Metastatic Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | Amgen | |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | NCT03653546 | Non-small Cell ... EGFR Gene Mutat... Brain Metastase... | AZD3759 Erlotinib Gefitinib | 18 Years - | Alpha Biopharma (Jiangsu) Co., Ltd. | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | NCT03653546 | Non-small Cell ... EGFR Gene Mutat... Brain Metastase... | AZD3759 Erlotinib Gefitinib | 18 Years - | Alpha Biopharma (Jiangsu) Co., Ltd. | |
| CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | NCT04933422 | Glioblastoma | CM93 | 18 Years - | Crimson Biopharm Inc. | |
| Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS) | NCT02810262 | Bone Metastases Lung Cancer | Bone metastases... | 18 Years - | Hospices Civils de Lyon | |
| Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | NCT04547777 | Glioma, Maligna... | D2C7-IT 2141-V11 | 18 Years - | Duke University | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
